Category: Disease Biology

Clinical Trials Diabetes News Weight-loss Drugs

Lilly’s Oral GLP-1 Orforglipron Demonstrates Superior Efficacy Over Semaglutide in Landmark Type 2 Diabetes Trial

Eli Lilly and Company

Eli Lilly and Company has announced breakthrough results from ACHIEVE-3, a head-to-head clinical trial that establishes orforglipron as a superior oral GLP-1 receptor agonist for type 2 diabetes management. The investigational medication outperformed oral semaglutide across all primary and key secondary endpoints, delivering clinically meaningful improvements in blood sugar control and weight loss. With FDA obesity approval expected in Q2 2026 and regulatory submissions already filed in over 40 countries, orforglipron represents a significant advancement in cardiometabolic treatment options.

Clinical Trials Autoimmune Diseases Healthcare & Pharmaceuticals News

Johnson & Johnson Announces Landmark TREMFYA Data: 80% of Patients Achieve Sustained Clinical Remission in Ulcerative Colitis Through 3 Years

JohnsonAndJohnson

Johnson & Johnson announces groundbreaking long-term clinical data revealing that TREMFYA (guselkumab) maintains sustained clinical, endoscopic, and histologic remission in adults with moderately to severely active ulcerative colitis through 3 years of treatment. The QUASAR long-term extension study demonstrates 80.8% clinical remission and 78.6% mucosal healing rates, setting new standards for inflammatory bowel disease management.

Clinical Trials Autoimmune Diseases News

Roche’s Gazyva/Gazyvaro Achieves Positive Phase III Results in Primary Membranous Nephropathy, Marking Historic Milestone for Autoimmune Kidney Disease Treatment

Roche

In a landmark announcement, Roche revealed that Gazyva (obinutuzumab) met its primary endpoint in the phase III MAJESTY trial for primary membranous nephropathy treatment. The trial data demonstrates superior clinical outcomes compared to tacrolimus, positioning Gazyva as a transformative therapy for patients with this chronic autoimmune kidney condition. With nearly 88,000 affected patients in the EU and over 96,000 in the US, primary membranous nephropathy represents a significant unmet medical need. Gazyva phase III results show the potential to become the first FDA and EMA-approved therapy specifically for this indication. The positive MAJESTY trial outcomes highlight Gazyva’s mechanism deep tissue B cell depletion via anti-CD20 targeting as an effective approach to halting disease progression and preserving kidney function in primary membranous nephropathy patients.

Regulatory Approval Autoimmune Diseases News

Amgen Wins EU Approval for UPLIZNA in Rare Muscle-Weakening Disease, Opening New Front in Autoimmune Battle

amgen

The European Commission has granted approval for Amgen’s UPLIZNA® (inebilizumab) as an add-on treatment for adults with generalized myasthenia gravis making it the first and only CD19-targeted therapy authorized in Europe for this rare, debilitating autoimmune muscle disease. The approval is backed by pivotal Phase 3 data from the landmark MINT trial.

Business Anti-obesity Drugs Diabetes News

Eli Lilly Released Q4 and 2025 Results; Projects $80B+ Revenue for 2026 as Oral Weight-Loss Drug Orforglipron Nears Approval

Eli Lilly and Company

Eli Lilly (LLY) shattered Q4 2025 expectations with $19.3 billion in revenue, marking a 43% year-over-year increase. Driven by the explosive demand for weight-loss treatments Mounjaro and Zepbound, the pharmaceutical giant issued a confident 2026 revenue guidance of $80B–$83B, signaling continued dominance in the metabolic health market.

Regulatory Autoimmune Diseases Healthcare & Pharmaceuticals News

Sanofi Anticipates Delay in FDA Regulatory Decision for Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis

sanofi

Sanofi anticipates that the US regulatory decision for its investigational drug, tolebrutinib, for non-relapsing secondary progressive multiple sclerosis (nrSPMS) will be delayed beyond the previous December 2025 target action date, with further guidance expected by the end of Q1 2026.

Regulatory Approval Autoimmune Diseases News

U.S. FDA Approves Amgen’s UPLIZNA® for Generalized Myasthenia Gravis in Adults

amgen

The FDA has approved Amgen’s UPLIZNA for adults with generalized myasthenia gravis (gMG) who are anti-AChR or anti-MuSK antibody positive. UPLIZNA is the first and only CD19-targeted B-cell therapy approved for this indication, offering a convenient dosing schedule of just two maintenance doses per year following the initial loading regimen. The approval is based on strong efficacy data from the Phase 3 MINT trial.

Regulatory Approval Autoimmune Diseases Healthcare & Pharmaceuticals News

Johnson & Johnson’s Imaavy Wins European Commission Approval for Generalized Myasthenia Gravis

JohnsonAndJohnson

Johnson & Johnson has secured European Commission approval for Imaavy (nipocalimab), a novel treatment for generalized myasthenia gravis (gMG). This authorization marks the first FcRn blocker approved in Europe for a broad population that includes both adults and adolescents (aged 12+), offering a new option for sustained disease control.

Clinical Trials Autoimmune Diseases Healthcare & Pharmaceuticals News

New 48-Week Data Shows TREMFYA® (guselkumab) Substantially Inhibits Joint Damage in Psoriatic Arthritis

JohnsonAndJohnson

New long-term data from the Phase 3b APEX study confirms that TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to substantially inhibit the progression of structural joint damage in patients with active psoriatic arthritis, with results sustained through 48 weeks.